Todays Report: The Financial Management Professionals Inc. reaches $193,000 position of Pfizer Inc. (PFE)

The Financial Management Professionals Inc. reaches $193,000 position  of Pfizer Inc. (PFE)

Financial Management Professionals Inc. boosted its stake in shares of Pfizer Inc. (NYSE:PFE) by 21.9% during the second quarter, Holdings Channel reports. The institutional investor owned 5,517 shares of the biopharmaceutical company’s stock after buying an additional 993 shares during the period. Financial Management Professionals Inc.’s holdings in Pfizer were worth $193,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Capital Investment Advisors LLC boosted its stake in Pfizer by 2.5% in the first quarter. Capital Investment Advisors LLC now owns 182,566 shares of the biopharmaceutical company’s stock valued at $5,411,000 after buying an additional 4,386 shares during the last quarter. Iberiabank Corp boosted its stake in Pfizer by 11.3% in the first quarter. Iberiabank Corp now owns 122,006 shares of the biopharmaceutical company’s stock valued at $3,616,000 after buying an additional 12,385 shares during the last quarter. CrestPoint Capital Management LLC boosted its stake in Pfizer by 122.5% in the first quarter. CrestPoint Capital Management LLC now owns 63,400 shares of the biopharmaceutical company’s stock valued at $1,879,000 after buying an additional 34,900 shares during the last quarter. M. Kraus & Co boosted its stake in Pfizer by 2.3% in the first quarter. M. Kraus & Co now owns 25,134 shares of the biopharmaceutical company’s stock valued at $874,000 after buying an additional 566 shares during the last quarter. Finally, BTR Capital Management Inc. boosted its stake in Pfizer by 603.0% in the first quarter. BTR Capital Management Inc. now owns 150,613 shares of the biopharmaceutical company’s stock valued at $4,464,000 after buying an additional 129,190 shares during the last quarter. 69.65% of the stock is owned by hedge funds and other institutional investors.

Shares of Pfizer Inc. (NYSE:PFE) traded down 0.5352% on Friday, hitting $33.4699. The stock had a trading volume of 8,412,975 shares. The company has a market cap of $203.02 billion, a P/E ratio of 29.6719 and a beta of 0.86. The company’s 50 day moving average price is $34.33 and its 200-day moving average price is $34.17. Pfizer Inc. has a 12 month low of $28.25 and a 12 month high of $37.39.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.62 by $0.02. Pfizer had a return on equity of 23.37% and a net margin of 14.88%. The firm earned $13.10 billion during the quarter, compared to analyst estimates of $13.01 billion. During the same period last year, the company earned $0.56 EPS. Pfizer’s quarterly revenue was up 10.9% compared to the same quarter last year. On average, analysts expect that Pfizer Inc. will post $2.46 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 1st. Shareholders of record on Friday, November 11th will be given a dividend of $0.30 per share. This represents a $1.20 dividend on an annualized basis and a yield of 3.57%. The ex-dividend date is Tuesday, November 8th. Pfizer’s dividend payout ratio (DPR) is presently 95.24%.

Several equities research analysts have weighed in on PFE shares. Vetr upgraded shares of Pfizer from a “buy” rating to a “strong-buy” rating and set a $37.94 price objective for the company in a research report on Monday, June 27th. Deutsche Bank AG reiterated a “buy” rating and set a $44.00 price target on shares of Pfizer in a research report on Thursday, August 18th. Credit Suisse Group AG reiterated an “outperform” rating and set a $40.00 price target on shares of Pfizer in a research report on Monday, August 22nd. Piper Jaffray Cos. set a $54.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research report on Tuesday, August 23rd. Finally, Jefferies Group set a $41.50 price target on shares of Pfizer and gave the stock a “buy” rating in a research report on Thursday, July 14th. Ten investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $38.78.

About Pfizer

Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.

Related posts

Leave a Comment